These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

631 related articles for article (PubMed ID: 19080272)

  • 1. Relationship between lower urinary tract symptoms and objective measures of benign prostatic hyperplasia: a Chinese survey.
    Wang JY; Liu M; Zhang YG; Zeng P; Ding Q; Huang J; He DL; Song B; Kong CZ; Pang J
    Chin Med J (Engl); 2008 Oct; 121(20):2042-5. PubMed ID: 19080272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between uroflowmetry, prostate volume, postvoid residue, and lower urinary tract symptoms as measured by the International Prostate Symptom Score.
    Ezz el Din K; Kiemeney LA; de Wildt MJ; Debruyne FM; de la Rosette JJ
    Urology; 1996 Sep; 48(3):393-7. PubMed ID: 8804492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association among the symptoms, quality of life and urodynamic parameters in patients with improved lower urinary tract symptoms following a transurethral resection of the prostate.
    Seki N; Yunoki T; Tomoda T; Takei M; Yamaguchi A; Naito S
    Neurourol Urodyn; 2008; 27(3):222-5. PubMed ID: 17580358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
    Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
    Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Quality of life assessment of the male with benign prostate hypertrophy].
    Nekić VC; Tiljak H; Petricek G; Soldo D; Nekić G; Buljan N
    Acta Med Croatica; 2007 Feb; 61(1):49-55. PubMed ID: 17593641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Change in International Prostate Symptom Score, prostrate-specific antigen and prostate volume in patients with benign prostatic hyperplasia followed longitudinally.
    Tsukamoto T; Masumori N; Rahman M; Crane MM
    Int J Urol; 2007 Apr; 14(4):321-4; discussion 325. PubMed ID: 17470162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant relationship of time-dependent uroflowmetric parameters to lower urinary tract symptoms as measured by the International Prostate Symptom Score.
    Itoh H; Kojima M; Okihara K; Ukimura O; Ushijima S; Kawauchi A; Miki T
    Int J Urol; 2006 Aug; 13(8):1058-65. PubMed ID: 16903930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relation of lower urinary tract symptoms with life-style factors and objective measures of benign prostatic enlargement and obstruction: an Italian survey.
    Tubaro A; La Vecchia C;
    Eur Urol; 2004 Jun; 45(6):767-72. PubMed ID: 15149750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of symptomatic BPE among Malaysian men aged 50 and above attending screening during prostate health awareness campaign.
    Teh GC; Sahabudin RM; Lim TC; Chong WL; Woo S; Mohan M; Khairullah A; Abrams P
    Med J Malaysia; 2001 Jun; 56(2):186-95. PubMed ID: 11771079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-term efficacy of naftopidil for treatment of lower urinary tract symptoms with benign prostatic hyperplasia].
    Akasaka T; Funaki H; Hirano S; Ohinata M; Fujishima M; Kudou T; Suzuki A; Iinuma M
    Hinyokika Kiyo; 2003 Apr; 49(4):189-93. PubMed ID: 12784711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Changes of urinary symptoms after transurethral resection of the prostate and its correlation with clinical parameters].
    Zhao Z; Wang G; Na YQ
    Zhonghua Wai Ke Za Zhi; 2007 Jul; 45(14):957-9. PubMed ID: 17961379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
    Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
    J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seasonal changes in symptom score and uroflowmetry in patients with lower urinary tract symptoms.
    Watanabe T; Maruyama S; Maruyama Y; Kageyama S; Shinbo H; Otsuka A; Ozono S
    Scand J Urol Nephrol; 2007; 41(6):521-6. PubMed ID: 17853015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Stief CG; Porst H; Neuser D; Beneke M; Ulbrich E
    Eur Urol; 2008 Jun; 53(6):1236-44. PubMed ID: 18281145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, randomized controlled study.
    Yokoyama T; Kumon H; Nasu Y; Takamoto H; Watanabe T
    Int J Urol; 2006 Jul; 13(7):932-8. PubMed ID: 16882058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey.
    Suzuki H; Yano M; Awa Y; Nakatsu H; Egoshi K; Mikami K; Ota S; Okano T; Hamano S; Ohki T; Furuya Y; Ichikawa T
    Int J Urol; 2006 Sep; 13(9):1202-6. PubMed ID: 16984553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and validation of a new treatment outcome score for men with LUTS.
    Weiss JP; Blaivas JG; Tash Anger JA; Di Blasio CJ; Panagopoulos G; Gerboc J
    Neurourol Urodyn; 2004; 23(2):88-93. PubMed ID: 14983416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function.
    Li MK; Garcia L; Patron N; Moh LC; Sundram M; Leungwattanakij S; Pripatnanont C; Cheng C; Chi-Wai M; Loi-Cheong N
    BJU Int; 2008 Jan; 101(2):197-202. PubMed ID: 18005205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.